GlassScriptPhysician profile
Matthew R Carns
NPI 1346420965
$1,381.83
in general payments reported to CMS, 2019-2025
24 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $80.17 · 2021: $153 · 2022: $98.27 · 2023: $414 · 2024: $373 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $913.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $435.67 | 2021-2024 | Zeposia |
| Abbvie INC. | $128.00 | 2020-2023 | Rinvoq |
| Fresenius Kabi USA, LLC | $111.93 | 2023 | Idacio |
| Romark Laboratories, Lc | $101.32 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $55.16 | 2021-2023 | |
| Pharmacosmos Therapeutics INC. | $49.56 | 2024-2025 | Monoferric |
| Organon LLC | $46.60 | 2021-2023 | Hadlima |
| Janssen Biotech, INC. | $44.99 | 2020-2022 | |
| Pfizer INC. | $38.94 | 2021-2025 | |
| Qol Medical, LLC | $38.51 | 2019-2025 | Sucraid |
| Gilead Sciences, INC. | $38.05 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $34.53 | 2023 | Rebyota |
| Lilly USA, LLC | $33.88 | 2025 | Omvoh |
| Merck Sharp & Dohme LLC | $31.99 | 2023-2024 | |
| Sandoz INC. | $29.70 | 2023 | Hyrimoz |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $27.93 | 2024 | |
| Digestive Care, INC. | $24.85 | 2024 | Pertzye |
| Daiichi Sankyo INC. | $23.12 | 2024 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $19.30 | 2021 | |
| Genzyme Corporation | $15.45 | 2022 | |
| Shire North American Group INC | $14.76 | 2019 | |
| Ucb, INC. | $14.31 | 2019 | |
| Novo Nordisk INC | $13.53 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $9.75 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Carns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.